Facebook Linkedin Twitter
Inside Precision Medicine Myriad to Develop CDx for BeiGene’s PARP Inhibitor BGB-290

Anti cancer drugs

Source: Myriad Genetics
Molecular Dx

Myriad to Develop CDx for BeiGene’s PARP Inhibitor BGB-290

Inside Precision Medicine Staff Writer -
0
Plasmacytoid variant of urothelial carcinoma
Molecular Dx

Loxo Oncology, Ventana in CDx Development Collaboration for Cancer Candidate Larotrectinib

Inside Precision Medicine Staff Writer -
0
Patrick Aloy
Informatics

In Silico Insights: Harnessing Bioinformatics to Find New Breast Cancer Drug Combinations

Diana Kwon -
0
DNA sequence with colored letters on black background containing mutation
Molecular Dx

Strata Oncology to Offer Patient ID and Enrollment for Epizyme Trial of NHL Candidate

Inside Precision Medicine Staff Writer -
0
Prostate Cancer Slide
Molecular Dx

GenomeDx Tests, Database to Help Astellas Identify Patients for Prostate Cancer Drug Xtandi

Inside Precision Medicine Staff Writer -
0
Dementia disease and a loss of brain function and memories
Molecular Dx

Researchers Link Effect of Cancer Drug With Alzheimer’s-Protecting Mutation

Inside Precision Medicine Staff Writer -
0
Source: NIH
Molecular Dx

New Sequencing Technique for Cisplatin Damaged DNA Unveiled

Inside Precision Medicine Staff Writer -
0
The Parsortix CTC isolation system.
News & Features

Case Study: Enabling a Paradigm Shift in Precision Medicine

Kyra Mumford, Ph.D. -
0
Source: Wikicommons/Oliver Byrne’s Elements of Euclid
Molecular Dx

The Pons Asinorum of Diagnostic Genomics

Stephen C. Peiper, M.D. -
0
Source: iStock/© evryka23
News & Features

A Match Made in Cancer—Fickle Kinases, Promiscuous Drugs

Inside Precision Medicine Staff Writer -
0
1...222324Page 23 of 24

Related Content

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine